SCHEMBL3866697

SCHEMBL3866697

COC(=O)c1cc(-c2cc(C)cs2)n(-c2ccc(C)cc2)n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
PTGS2 P35354 1/20 0.46
SMPD1 P17405 1/20 0.46
CA9 Q16790 3/20 0.45
PPP1CA P62136 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
RPA1 P27694 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPK9 P45984 1/20 0.39
RXRA P19793 1/20 0.39
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
FAAH O00519 1/20 0.39
MGLL Q99685 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3865153 0.92 PTGS2 (0.56) SMN1; SMN2PTGS2CA9PPP1CAKMT2A
SCHEMBL3863677 0.92 SMN1; SMN2 (0.56) SMN1; SMN2PTGS2SMPD1PPP1CAKMT2A
SCHEMBL3863718 0.92 RPA1 (0.50) SMN1; SMN2PTGS2CA9KMT2AMEN1
SCHEMBL3873187 0.92 SMPD1 (0.51) SMN1; SMN2PTGS2SMPD1CA9PPP1CA
SCHEMBL3876521 0.92 SMN1; SMN2 (0.46) SMN1; SMN2PTGS2KMT2AMEN1RPA1
SCHEMBL3870130 0.89 KDM1A (0.43) SMN1; SMN2PTGS2RPA1
SCHEMBL3870918 0.89 PTGS2 (0.44) SMN1; SMN2PTGS2CA9CA1CA2
SCHEMBL14728116 0.82 SMPD1 (0.64) SMN1; SMN2PTGS2SMPD1CA9PPP1CA
SCHEMBL3864153 0.81 ALDH1A1 (0.40) SMN1; SMN2KMT2AMEN1ALDH1A1RXRA
SCHEMBL877377 0.77 SMPD1 (0.58) SMN1; SMN2PTGS2SMPD1CA9PPP1CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2009-01-01 US disclosed
US-7442802-B2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2008-10-28 US disclosed
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-31 US disclosed
US-7087630-B2 Cyclooxygenase 2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-08 US disclosed
EP-1534683-A4 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2005-08-24 EP disclosed
EP-1534683-A2 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2005-06-01 EP disclosed
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. 2004-03-18 US disclosed
WO-2004002409-A2 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 SMN1; SMN2 2470/4885PTGS2 1/4885SMPD1 1857/4885
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 SMN1; SMN2 2470/4885PTGS2 1/4885SMPD1 1857/4885
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE PTGS2, PTGIS, PTGES2 SMN1; SMN2 2470/4885PTGS2 1/4885SMPD1 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.